Are We in Store for More M&A in the Liquid Biopsy Space?
M&A activity in the liquid biopsy space is picking up as Bio-Techne said it will acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones.
IVD
Monitoring is Key in Precipio’s Liquid Biopsy Success
Precipio merged with Transgenomics last year to expand its liquid biopsy prowess.
Collaboration Needed to Fight Antimicrobial Resistance
Diagnostics manufacturers and even medical device innovators can play roles, says an expert working to raise awareness.
Bringing AI to Colorectal Cancer Screening
Freenome has initiated a clinical study to help bring an AI-Genomics blood test for colorectal cancer to the U.S. market.
Grail Brings VC Funding to $1.5B with Latest Round
Grail raises $300 million in Series C round to give massive boost to the development of its liquid biopsy applications for cancer.
Top Tips For R&D Managers Looking To Crack The Lateral Flow Market
Industry expert shows how to navigate the Lateral Flow market.
Proposed Guidelines Could Leave Some PTSD Patients in the Dark
A new study shows proposed changes in the International Classification of Diseases (ICD) guidelines could lead to a reduction in the diagnosis of PTSD patients.
GeneSight Weeds Out Ineffective Drug Therapies for Depression
Myriad Genetics presented results from a 24-week study that showed Major Depressive Disorder patients were 50% more likely to achieve remission and 30% more likely to respond to treatment using the GeneSight Psychotropic genetic test.
Orion Sheds Diagnostic Unit for $200M Plus Milestones
Orion Diagnostica develops Point-of-Care tests and earned about $67 million in sales for its most recent reported year.
Companion Diagnostics Space Warms Up with Collaboration
Bristol-Myers Squibb has teamed up with Illumina to develop companion diagnostics for oncology immunotherapies.
Qiagen To Unveil 2 Liquid Biopsy Tests at AACR
Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.
Who Needs Needles? Not These Medtech Companies
These seven medtech companies aren't just moving the needle, they're getting rid of it all together!
Fresh Off IPO, Quanterix Meets Its DestiNA
Quanterix teams up with DestiNA to develop assays to detect liver toxicity in patients.
This Liquid Biopsy Can Rule Out Early-Stage Lung Cancer
A new study has confirmed the accuracy of the Xpresys Lung 2 test developed by Integrated Diagnostics.
In a First, Qiagen Turns Focus to Prenatal Testing
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
SQI Test Detects Heart Attack Before It Happens
SQI Diagnostics and Predictive Health bring cardiovascular diagnostics to the forefront with the launch of a serum-based heart attack probability test.